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PMI25
THE STATUS OF QUALITY OF LIFE DATA IN
HEALTH TECHNOLOGY ASSESSMENTS:
EVIDENCE FROM PUBLISHED NICE
APPRAISALS
Kind P
Outcomes Research Group,York, UK
The requirements for health technology assessments con-
ducted for the National Institute for Clinical Effectiveness
(NICE) are similar to those deemed applicable by other
groups (for example the Washington Panel). Beneﬁts 
are represented in terms of quality-adjusted life years
(QALYs) where the quality adjustment is based on the
utility weights of the relevant reference population. 
A single index, utility-weighted scoring function that cap-
tures the preferences of the general population is prob-
lematic. Access to such a weighting system is typically
mediated through quality of life (QoL) data that capture
the beneﬁts of therapy. Where QoL data do not meet
these requirements then alternative methods have to be
adopted.
OBJECTIVES: To assess the status of QoL data in the
published NICE record and to review the procedures used
to estimate utilities based on those data.
METHODS: The 31 assessment reports published by
NICE in the period 1999–2001 were systematically
reviewed. Particular attention was paid to information
provided about QoL measures incorporated in the studies
referenced by the appraisal. Of special note was the type
of measure (i.e. index or proﬁle), its weighting system and
the source of reference values.
RESULTS: QoL data was reported with varying com-
pleteness. This contrasts with the data abstraction cover-
ing other aspects of the appraisal. Methods used to weight
QoL data ranged from the deliberation of expert panels
to the use of standarised QoL measures with utility
weights elicited from the general population. Evidence 
of subjective assessment of QALY estimates included 
their being “based on reasonable assumptions using well-
accepted measures”.
CONCLUSIONS: Evidence of the variability in the
quality of QoL data and their use in QALY calculations
indicates the need for clearer guidance and rigour in
reporting and analysis. Findings impact on all parties to
this form of technology assessment.
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FEATURES OF GOMPERTZ FUNCTIONS IN
MODELING MORTALITY RATES
Wendland G1, Lauterbach K2
1Guido Wendland, Cologne, NW, Germany; 2University of
Cologne, Cologne, Germany
OBJECTIVES: Despite their surprisingly good ﬁt of
current mortality data, Gompertz-functions are rather
seldom used in outcome research. The main objective is
to show some interesting methodological features of the
Gompertz function encouraging a more wide-spread use
in modeling mortality rates beyond the time frame of clin-
ical trials.
METHODS: Current mortality data of the Statistical
Yearbook of Germany are closely ﬁtted by Gompertz
functions (Rx = R0 exp(bx), x = age) which involves esti-
mating parameters b und R0 by non-linear iterative
regression. Several authors have observed that in a series
of Gompertz-functions from the same underlying popu-
lation (i.e. life tables from different years, different sub-
groups, different regions etc.) the two parameters are
closely related as: lnR0 = ab + b, where a < 0, b Œ IR.
Based on this relation, it is shown how to determine Gom-
pertz functions for speciﬁc study cohorts by specifying a
standardised mortality ratio (SMR) at a certain age. In
practical applications this SMR can be estimated from
clinical trials data.
RESULTS: All Gompertz-functions satisfying the relation
lnR0 = ab + b intersect at (-a, exp(b)). If the SMR is ﬁxed
at an age of x¢ then a Gompertz-function satisfying this
condition is given by b2 = ln(SMR)/(x¢ + a) + b1, and R20
= exp(ab2) exp(b), where (b2, R20) is the pair of parame-
ters of the new Gompertz-function, and the pair (b1, R10)
belongs to the baseline Gompertz-function. Furthermore
it holds that the hazard ratio at any age is given by the
ratio (R20/R10)x/a+1.
CONCLUSIONS: The more frequent use of Gompertz-
Functions in the area of modeling is motivated by the
good ﬁt of mortality data in the general population. 
Furthermore, this analysis shows how these results can 
be extended to speciﬁc subgroups of patients, when clin-
ical trials data only provide little mortality data. The
analysis of high-risk groups in disease prevention seems
a sensible context for applying these results.
PMI27
A UTILITY-MAXIMISATION MODEL OF CHOICE
BETWEEN MEDICAL INTERVENTIONS
INVOLVING RISK
Walshe R
University of Cologne, Cologne, Germany
OBJECTIVES: To develop a utility-maximisation model
of choice between alternative treatments of speciﬁc dis-
orders on the basis of microeconomic consumption
theory. The model is to take into account patients’ pref-
erences for clinical procedures, possible outcomes and
risks involved in alternative treatments.
METHODS: The optimisation problem facing a patient
is presented by geometrical and algebraic analysis using
an ordinal von Neumann Morgenstern (vNM) utility
function in a simple example involving two treatment
alternatives, T1 and T2. As the treatments are perfect sub-
stitutes, the ratio of marginal utilities (dT2/dT1) which
determines the slope of a patient’s indifference curves is
constant and can be identiﬁed by means of a modiﬁed
standard gamble (MSG). By including relative prices of
220 Abstracts
interventions, optimal allocation decisions are derived,
hypothetically assuming a market context.
RESULTS: vNM utility functions are developed for the
alternative treatments and a “no treatment” option (T0)
on the basis of outcome and probability data from clini-
cal research. Utilities of procedures and outcomes can be
identiﬁed empirically. This requires a preference ordering
of treatment alternatives and MSG questions relating to
hypothetical treatments. The number of MSG questions
and hypothetical treatments (n-2) depends on the number
of vNM variables (n). This procedure identiﬁes the ratio
of marginal utilities of T1 and T2, dT2/dT1. The inclu-
sion of relative prices of T1 and T2, pT1/pT2, into the
model allows the prediction of utility-based treatment
choices and the application of the model in resource 
allocation.
CONCLUSIONS: The main advantages of this model are
its ability to predict utility-based decisions incorporating
risk preferences and to avoid the need for methodologi-
cally delicate techniques such as sensitivity analysis and
discounting. The practical beneﬁts of this approach
remain to be determined within empirical evaluations.
PMI28
ELECTRONIC DATA COLLECTION OF 
PATIENT-REPORTED OUTCOMES
Schmier JK1, Rentz AM1, Dennison CR1, Jones R2,
Rothman M2
1MEDTAP International, Inc, Bethesda, MD, USA; 2Health
Economics, Johnson & Johnson, Raritan, NJ, USA
Technological advances have resulted in Electronic Data
Collection (EDC) increasingly replacing traditional paper
and pencil questionnaire data collection of clinical trial
data, including Patient Reported Outcomes (PRO). Our
objective was to assess EDC compared to traditional
methods of PRO data collection to assist in selecting a
method.
METHODS: A literature search identiﬁed EDC-related
publications within the last 5 years; a web search identi-
ﬁed regulatory and institutional guidance documents.
RESULTS: Of 584 articles identiﬁed, approximately 60
articles using EDC to assess PRO data were selected for
full review. Four forms of EDC were identiﬁed: personal
digital assistants (PDAs), personal computers (PCs), inter-
active voice response (IVR) systems, and electronic 
mail. PDAs, PCs, and IVR may offer higher data quality
than pencil and paper; data entry can be immediate, logic
checks can be incorporated, thus reducing the number of
data queries. Compliance with data collection protocols
has been shown to be higher using EDC and evidence
indicates patients and clinicians prefer it. All methods
require back-up and security procedures to ensure data
integrity. Studies examining EDC costs have consistently
found paper and pencil methods more expensive espe-
cially as volume increases. PDAs, PCs, and IVR have been
used in clinical trials to assess PROs but email lacks
anonymity thereby making it unsuitable. Ecological
momentary assessment (EMA) is real-time or scheduled
assessment of PRO; patients are prompted to complete
assessments in their current environment. EDC facili-
tates EMA data collection and enhances data volume and
quality. The FDA requires extensive documentation of
audit trails, but has not released requirements for EDC
procedures.
CONCLUSIONS: EDC demonstrates advantages for the
collection of high quality data quickly. As new technolo-
gies proliferate, clinical trials can take advantage of EDC
to enhance data quality and reduce trial-related costs with
precautions to ensure data security.
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PATIENT-GENERATED OUTCOMES: FAD OR
HERE TO STAY?
Patel KK,Veenstra DL
University of Washington, Seattle, WA, USA
Patient-generated outcomes attempt to capture the indi-
vidualistic nature of quality of life. Although this is an
attractive concept, a critical review of these instruments
is needed to assess their applicability in a clinical trial
setting.
OBJECTIVE: To provide a critical review of four patient-
generated quality of life instruments: Patient-Generated
Index (PGI), Schedule for the Evaluation of Individual
Quality of Life (SEIQoL), Repertory Grid, and Asthma
Quality of Life Questionnaire (AQLQ).
METHODS: We conducted a systematic literature review
of available computerized databases, the Quality of Life
Research Journal and consulted experts in the ﬁeld. We
abstracted data from the studies and constructed a matrix
comparing the four instruments based on their psycho-
metric properties and current use in quality of life
research.
RESULTS: The PGI and SEIQoL have been shown to be
reliable and valid in several different patient populations
and disease states; however, neither have been used in a
clinical trial. The SEIQoL-DW, in addition, has been
shown to be practical and acceptable to patients. The
Repertory Grid has been shown to be reliable, valid and
practical, but has only been used in one observational
study. The AQLQ is a disease-speciﬁc instrument that is
only partially patient-generated. It has not only shown to
be reliable, valid and practical, but has also been used in
clinical trials as a sole measure of quality of life.
CONCLUSION: Patient-generated outcomes may not be
generally useful in a clinical trial setting. However, hybrid
instruments, such as the AQLQ, may be applicable in a
clinical trial setting. The primary role of patient-
generated outcome measures is as an adjunct measure or
to guide individual patient treatment decisions.
